Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 3Hematologic Neoplasms 2Teratoma 1Stroke 1Pulmonary Disease, Chronic Obstructive 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Failure, Chronic 1Hepatitis B 1Hematopoietic and Lymphatic System Neoplasm 1Endometrial Clear Cell Adenocarcinoma 1Endodermal Sinus Tumor 1Diabetes Mellitus 1Coronary Artery Disease 1Colonic Neoplasms 1Carcinoma, Embryonal 1COVID-19 1Breast Neoplasms 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

tocilizumab 1Standard of Care 1Practice Guidelines as Topic 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Kidney Failure, Chronic × Practice Guidelines as Topic × Clear all
NCT04361552 2020-06-18

Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)

Emory University

Phase 3 Withdrawn
Genitourinary

COVID-19, Coronary Artery Disease, Diabetes Mellitus, Kidney Failure, Chronic, Neoplasms, Stroke, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡